Table 3 Prospective SPC results at week 12
Study IMP 24011[15] | Treatment Group | Safe Psoriasis Control (SPC)* |
|---|---|---|
Total study group | Placebo (n = 165) | 12 (7.3 %) |
| Â | Efalizumab 1.0 mg/kg/wk (n = 329) | 113 (34.3 %) |
High need group | Placebo (n = 117) | 4 (3.4 %) |
| Â | Efalizumab 1.0 mg/kg/wk (n = 221) | 73 (33.0 %) |